Blood test boosts Alzheimer's diagnosis accuracy to 94.5%, clinical study shows

Original Article ↗ Hacker News Discussion ↗

Role and Setting of the Blood Test

  • Test is presented as an adjunct to specialist evaluation, not a stand‑alone population screen.
  • In the study, clinicians’ diagnostic agreement with the final diagnosis rose from ~75.5% to 94.5% after seeing the blood biomarker.
  • Commenters stress this is for patients already showing significant cognitive decline (e.g., memory clinics), not for asymptomatic screening.

Debate Over “94.5% Accuracy”

  • Several people question the headline: “accuracy” is reported, but sensitivity, specificity, and prevalence are largely absent.
  • With low prevalence, even a high “accuracy” can yield many false positives; one commenter shows you can exceed 94% “accuracy” by always predicting “no disease.”
  • Others note 94.5% is not “terrible” within neurology, where most serious diagnostics have substantial false positive/negative rates.
  • One detailed critique argues the study mostly shows reclassification of patients after testing, without a true gold standard or longitudinal follow‑up to prove that reclassification is actually more correct.

Why Diagnose if There’s No Cure?

  • Many emphasize strong personal reasons to know early: estate and guardianship planning, end‑of‑life and euthanasia decisions, choice of living arrangements, and giving families time to adjust.
  • Others highlight diagnostic clarity as a relief in itself and a way to redirect workup toward other causes if the test is negative.
  • A skeptical camp argues early knowledge may cause years of psychological harm without clear benefit, and that basic planning should be done regardless.

Treatment and Research Implications

  • Commenters cite modest but real slowing from monoclonal antibodies (e.g., lecanemab, donanemab; a newer candidate Trontinemab), with anecdotes of stabilized function in early‑treated patients.
  • Shingles vaccination, herpes infections, gut microbiome, sleep, diet (including ketogenic diets), and 40 Hz sensory/ultrasound stimulation are mentioned as emerging or speculative avenues.
  • Early, more precise diagnosis is seen as crucial for:
    • Building large, well‑stratified cohorts.
    • Studying pre‑symptomatic stages and subtypes.
    • Testing preventive or disease‑modifying therapies before irreversible damage.

Ethical, Social, and Systemic Concerns

  • Fears about false positives leading to stigma, lost promotions, or insurance problems, especially for working‑age adults in safety‑critical jobs.
  • Some call for strong privacy protections and social safety nets before widespread deployment.
  • In single‑payer systems, commenters note the need to weigh the cost of new diagnostics against competing priorities (e.g., other screenings).